Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent or assent~* Subject has completed study TR02-108, and has been compliant with the study protocol~* Women of childbearing potential must agree to use reliable methods of contraception for the duration of the study~Key Exclusion Criteria:~* Subject met any of the listed criteria for study drug discontinuation in protocol TR02-108.~* Abnormal laboratory assessments including LFT (≥ 3× upper limit of normal \[ULN\]), serum creatinine (\> 2× ULN) and absolute neutrophil count \[ANC\] (\< 1000).~* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.~* History of alcohol, medication or illicit drug abuse within the 6 months prior to consent.~* Smoking tobacco or any substance within 6 months prior to consent or anticipated inability to refrain from smoking throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAI (Type: EXPERIMENTAL): 590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).

Based on this trial design, predict the completion outcome and termination type (if applicable).